Ultime notizie per Patterson Cos (NASDAQ:PDCO) Azioni

Patterson Cos

Patterson Companies Inc is a dental distributor and wholesaler of consumable products and equipment operating through two business segments, Patterson Dental, and Patterson Animal Health. The company's segment includes Dental, Animal Health, and Corporate. It generates maximum revenue from the Animal Health segment. Geographically, it derives its revenue from the United States, the United Kingdom, and Canada. The firm derives almost all of its revenue from the United States.

Patterson Companies

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

PDCO

SCLX

Scopri le tre azioni sanitarie più promettenti con un indice RSI basso: un&#39;opportunità di investimento imperdibile per settembre 2024.

3 azioni sanitarie pronte a decollare: è ora di investire?

Dividends

Price Target

Analyst Ratings

Scopri le 3 azioni sanitarie con dividendi superiori al 3% consigliate dai migliori analisti di Wall Street.

Dividendi oltre il 3%? Le azioni scelte dai migliori analisti

Patterson Companies Inc

In the preceding three months, 6 analysts have released ratings for Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $25.33, a high estimate of $29.00, and a low estimate of $22.00. Experiencing a 7.89% decline, the current average is now lower than the previous average price target of $27.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1728417619_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Patterson Cos. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Michael Minchak</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Patterson Cos. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Patterson Cos compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Patterson Cos's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Patterson Cos's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PDCO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Patterson Cos analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Patterson Cos Better</h2>
Patterson Companies Inc is a dental distributor and wholesaler of consumable products and equipment operating through two business segments, Patterson Dental, and Patterson Animal Health. The company's segment includes Dental, Animal Health, and Corporate. It generates maximum revenue from the Animal Health segment. Geographically, it derives its revenue from the United States, the United Kingdom, and Canada. The firm derives almost all of its revenue from the United States.
<h3>Unraveling the Financial Story of Patterson Cos</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Patterson Cos's financials over 3 months reveals challenges. As of 31 July, 2024, the company experienced a decline of approximately -2.22% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Patterson Cos's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.4%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Patterson Cos's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.48% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Patterson Cos's debt-to-equity ratio is below the industry average at 0.94, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

6 Analysts Have This To Say About Patterson Cos

Evercore ISI Group analyst Ross Muken maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a In-Line and lowers the price target from $23 to $22.

Evercore ISI Group Maintains In-Line on Patterson Cos, Lowers Price Target to $22

Patterson expects to close the transactions during its second fiscal quarter of FY2025.

Patterson Companies Inks Two Separate Acquisition Agreements For Its Animal Health Business – Infusion Concepts In UK And Mountain Vet Supply In US; Terms Not Disclosed

Patterson Companies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pdco#NASDAQ">PDCO</a>) is well poised for growth in the coming quarters, courtesy of its broad product line. The optimism, led by a strong performance of certain business segments during first-quarter fiscal 2024 and a few notable acquisitions, is expected to contribute further. Integration risks and stiff competitive forces persist.
Shares of this Zacks Rank #3 (Hold) company have lost 24.6% in the past year compared with the industry&#39;s 6.1% decline. The S&amp;P 500 Index has increased 5.9% during the same time frame.
The renowned global dental and animal health company has a market capitalization of $1.82 billion. It projects 5.9% growth for the next five years and expects to maintain its strong performance going forward. Patterson Companies&#39; earnings missed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average negative surprise of 10.78%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/66/77100.jpg?v=775213013" />
Image Source: Zacks Investment Research
Let&#39;s delve deeper.
<h2>Upsides</h2>
Broad Product Spectrum: We are optimistic about Patterson Companies&#39; wide range of consumable supplies, equipment and software, and value-added services. A notable offering from PDCO is a private-label brand named Pivotal. It continues to add stock-keeping units to its broader private-label portfolio. The company&#39;s NaVetor is an integrated cloud-based veterinary practice management software for its Animal Health segment.
In June, PDCO launched new integrations for DentalXChange to provide additional electronic insurance processing and electronic patient statement solutions. In May, it announced a new product, Patterson CarePay+, to provide dental offices with software solutions for patient financing, dental insurance plans and payment processing.
Acquisitions &amp; Alliance: We are upbeat about PDCO&#39;s strategy of expanding its business via strategic acquisitions. In July, Patterson Dental Canada collaborated with Pearl to expand its Second Opinion AI disease detection capabilities&#39; reach in the Canadian dental market. By integrating Second Opinion within Patterson Dental Canada&#39;s leading software platforms, such as Eaglesoft, Fuse and Dolphin, the partnership aims to elevate the standard of dental care across North America.
During 2023, Patterson Companies completed its acquisition of the Texas-based companies, Veterinary Practitioners and Animal Care Technologies, which provide innovative solutions to veterinary practices through data extraction and conversion, staffing and video-based training services. In 2022, the company announced the acquisition of substantially all the assets of Dairy Tech, Inc., which provides pasteurizing equipment and single-use bags.
Fulfillment Facility Modernization to Optimize Supply: PDCO started strategic modernization of its existing fulfillment facilities and capabilities. It is adding new technologies, such as robots, to automate order picking and enhance the fulfillment pace.
PDCO is also focusing on expanding its fulfillment capacity by opening next-generation centers across several countries that will help build sustainable and more efficient channel capabilities. The company&#39;s strategic investments in fulfillment centers should help alleviate capacity constraints, boost distribution capabilities and enhance growth.
To support its facility modernization and expansion, PDCO has allocated $51.2 million in capital spending during fiscal 2024. The amount has increased 20.8% from the prior-year level.
Strong Q1 Results: Patterson Companies&#39; revenues and earnings missed estimates in the first quarter of fiscal 2024, reflecting the negative impact of a cybersecurity attack on its claims processing vendor, Change Healthcare. The impact is likely to alleviate in the upcoming quarters, potentially improving the top and bottom-line performance. Continued growth in the production animal business supported sales in the Animal Health segment.
PDCO has been making significant investments in developing its software and value-added services offerings across both its Dental and Animal Health segments. These are likely to drive the demand for its products.
<h2>Downsides</h2>
Stiff Competition: The U.S. dental products distribution industry is highly competitive and consists chiefly of national, regional and local full-service and mail-order distributors. Patterson Companies needs to continue to introduce newer products in the market to withstand competitive pressure. Failure to do so can dilute its market share.
Integration Risks: PDCO has been on an acquisition spree, which is improving its revenue opportunities but aggravating integration risks. Regular acquisitions are also a distraction for management and are likely to impact organic growth. This may limit the company&#39;s future expansion initiatives and worsen its risk profile.
<div class="chart_embed">
<h3>Patterson Companies, Inc. Price</h3>
<img alt="Patterson Companies, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/d7/1725957492.png" style="height:251px; width:572px" title="" />
Patterson Companies, Inc. price | Patterson Companies, Inc. Quote
</div>
<h2>Estimate Trend</h2>
The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $6.62 billion, indicating a 0.8% increase from the previous year&#39;s level. The consensus mark for adjusted earnings per share is pinned at $2.33, implying a 1.3% year-over-year improvement.
<h2>Stocks to Consider</h2>
Some better-ranked stocks in the broader medical space are DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), Quest Diagnostics Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and Boston Scientific Corporation.
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 24.2%.
DaVita&#39;s shares have risen 56.9% compared with the industry&#39;s 27.5% growth in the past year.
Quest Diagnostics, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 6.2%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.3%.
Quest Diagnostics&#39; shares have risen 21.6% compared with the industry&#39;s 27.5% growth in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Boston Scientific&#39;s shares have rallied 50.8% compared with the industry&#39;s 17.2% growth in the past year.
<a href="https://www.zacks.com/stock/news/2334054/here-s-why-you-should-retain-pdco-stock-in-your-portfolio-for-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2334054">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Large Cap

Financing

Offerings

Small Cap

Here's Why You Should Retain PDCO Stock in Your Portfolio for Now

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Scilex Holding Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>)</h3>
<ul>
<li>On Aug. 29, Scilex Holding announced the FDA final approval to precision dosing for GLOPERBA label. The company's stock fell around 23% over the past month and has a<a href="https://www.benzinga.com/quote/SCLX"> 52-week low of $0.73</a>.</li>
<li>RSI Value: 27.36</li>
<li>SCLX Price Action: Shares of Scilex Holding fell 1.9% to close at $1.02 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091024&amp;t=be2bearmibe3na1"> latest SCLX news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="837" height="761" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10072250/image-1-20.png" alt="" class="wp-image-539556" style="width:660px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10072250/image-1-20.png 837w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10072250/image-1-20-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10072250/image-1-20-768x698.png 768w" sizes="(max-width: 837px) 100vw, 837px" /></a></figure>
<h3 class="wp-block-heading">Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Aug. 28, Patterson Companies' first-quarter 2025 net sales of $1.54 billion, down 2.2% year-over-year. "Our first quarter results fell short of our expectations, primarily due to the greater than anticipated impact of the Change Healthcare cybersecurity attack on the value-added services category in our dental segment, along with lower sales in our companion animal business and the timing of certain corporate expenses," said Don Zurbay, president and CEO. The company's stock fell around 15% over the past month It <a href="https://www.benzinga.com/quote/PDCO">has a 52-week low</a> of $20.17.</li>
<li>RSI Value: 26.32</li>
<li>PDCO Price Action: Shares of Patterson Companies fell 1.1% to close at $20.48 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the t<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091024&amp;t=be2bearmibe3na1">rend in PDCO stock. </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10072436/image-72.png" alt="" class="wp-image-539559" style="width:679px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10072436/image-72.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10072436/image-72-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10072436/image-72-768x708.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">AMN Healthcare Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>)</h3>
<ul>
<li>On Aug. 8, AMN Healthcare issued third-quarter consolidated revenues guidance below estimates. &#8220;In the second quarter, we made important progress in strengthening AMN&#8217;s position with clients in every part of the market for total talent solutions in healthcare,&#8221; said Cary Grace, President and Chief Executive Officer of AMN Healthcare. The company's shares fell around 13% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/AMN">low of $43.00</a>.</li>
<li>RSI Value: 27.11</li>
<li>AMN Price Action: Shares of AMN Healthcare gained 0.1% to close at $45.70 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091024&amp;t=be2bearmibe3na1">breakout in AMN shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="877" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10072528/image-73.png" alt="" class="wp-image-539561" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10072528/image-73.png 877w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10072528/image-73-300x290.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/10072528/image-73-768x742.png 768w" sizes="(max-width: 877px) 100vw, 877px" /></a></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40785814/dow-jumps-over-1-following-last-weeks-selloff-investor-sentiment-improves-but-fear-greed-index-rema">Dow Jumps Over 1% Following Last Week&#8217;s Selloff: Investor Sentiment Improves, But Fear &amp; Greed Index Remains In &#8216;Fear&#8217; Zone</a></li>
</ul>

Top 3 Health Care Stocks That Could Blast Off In September

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>)</h3>
<ul>
<li>Dividend Yield: 4.93%</li>
<li>Baird analyst Jeff Johnson maintained a Neutral rating and cut the price target from $30 to $28 on Aug. 29. This analyst has an accuracy rate of 78%.</li>
<li>Evercore ISI Group analyst Ross Muken maintained an In-Line rating and lowered the price target from $25 to $23 on Aug. 29. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On Aug. 28, Patterson Companies reported worse-than-expected first-quarter adjusted EPS and sales.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://pro.benzinga.com/dashboard">latest PDCO news</a>.</li>
</ul>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 3.01%</li>
<li>Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $215 on Sept. 3. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $167 to $169 on July 18. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: Johnson &amp; Johnson will host a conference call on Tuesday, Oct. 15th to review third-quarter results.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://pro.benzinga.com/dashboard"> trend in JNJ stock</a>.</li>
</ul>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 4.58%</li>
<li>RBC Capital analyst Ben Hendrix reiterated an Outperform rating with a price target of $68 on Sept. 4. This analyst has an accuracy rate of 76%.</li>
<li>Barclays analyst Andrew Mok maintained an Equal-Weight rating and cut the price target from $65 to $63 on Aug. 8. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On Aug. 14, CVS Health named Heidi Capozzi Executive Vice President, Chief People Officer.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://pro.benzinga.com/dashboard">breakout in CVS shares.</a></li>
</ul>

<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy"> Jim Cramer: Oklo Is Losing Money &#8216;Hand-Over-Fist,&#8217; But This Private Equity Stock Is A Buy</a></li>
</ul>

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

UBS analyst Michael Cherny maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a Neutral and lowers the price target from $27 to $24.

UBS Maintains Neutral on Patterson Cos, Lowers Price Target to $24

JP Morgan analyst Michael Minchak maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a Neutral and lowers the price target from $29 to $26.

JP Morgan Maintains Neutral on Patterson Cos, Lowers Price Target to $26

B of A Securities analyst Michael Cherny maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a Buy and lowers the price target from $31 to $29.

B of A Securities Maintains Buy on Patterson Cos, Lowers Price Target to $29

Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $26.6, along with a high estimate of $29.00 and a low estimate of $23.00. A 6.34% drop is evident in the current average compared to the previous average price target of $28.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1724932849_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Patterson Cos. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$25.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Michael Minchak</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Patterson Cos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Patterson Cos compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Patterson Cos's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Patterson Cos's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PDCO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Patterson Cos analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Patterson Cos's Background</h2>
Patterson Companies Inc is a dental distributor and wholesaler of consumable products and equipment operating through two business segments, Patterson Dental, and Patterson Animal Health. The company's segment includes Dental, Animal Health, and Corporate. It generates maximum revenue from the Animal Health segment. Geographically, it derives its revenue from the United States, the United Kingdom, and Canada. The firm derives almost all of its revenue from the United States.
<h3>Understanding the Numbers: Patterson Cos's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Patterson Cos's revenue growth over a period of 3 months has been noteworthy. As of 30 April, 2024, the company achieved a revenue growth rate of approximately 0.09%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Patterson Cos's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.89% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Patterson Cos's ROE stands out, surpassing industry averages. With an impressive ROE of 6.8%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Patterson Cos's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Patterson Cos's debt-to-equity ratio is below the industry average. With a ratio of 0.76, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 5 Analyst Recommendations For Patterson Cos

Baird analyst Jeff Johnson maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a Neutral and lowers the price target from $30 to $28.

Baird Maintains Neutral on Patterson Cos, Lowers Price Target to $28

Evercore ISI Group analyst Ross Muken maintains Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) with a In-Line and lowers the price target from $25 to $23.

Evercore ISI Group Maintains In-Line on Patterson Cos, Lowers Price Target to $23

Patterson Companies Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) first-quarter 2025 net sales of $1.54 billion, down 2.2% year-over-year.
Wall Street expected a <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">net sales of $1.59 billion</a>. Internal sales <a href="https://www.benzinga.com/pressreleases/24/08/b40596866/patterson-companies-reports-fiscal-2025-first-quarter-operating-results" target="_blank" rel="noreferrer noopener">increased 2.8%</a>.
&#8220;Our first quarter results fell short of our expectations, primarily due to the greater than anticipated impact of the Change Healthcare cybersecurity attack on the value-added services category in our dental segment, along with lower sales in our companion animal business and the timing of certain corporate expenses,&#8221; said Don Zurbay, president and CEO.
The company reported dental segment sales of $550.4 million. Internal sales increased 2.8%. Internal sales of consumables&nbsp;decreased 2.1%.&nbsp;
Internal sales of equipment decreased 2.4%. Internal sales of value-added services decreased 6.7% compared to the prior year period, primarily due to the negative impact of the cybersecurity attack on Change Healthcare.
Animal Health segment sales reached $982.4 million. Internal sales fell 2.8%. Internal sales of consumables declined 3.0%, equipment decreased 3.8%, and value-added services increased 8.3%.&nbsp;
Adjusted EPS of 24 cents, down from 40 cents a year ago, and missed the consensus of 32 cents.
&#8220;In light of these factors and against the backdrop of a challenging macroeconomic environment, we are taking dedicated cost and management actions across Patterson to deliver on our financial plan for fiscal 2025 and maintaining a strategic focus on supporting our customers with the deep and differentiated value-proposition they expect from us,&#8221; Zurbay added.
Outlook: Patterson reaffirmed 2025 adjusted EPS guidance of $2.33-$2.43 versus consensus of $2.36.
Price Action: PDCO stock is down 9.11% during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40573775/eli-lilly-releases-cheaper-zepbound-vials-priced-upto-50-lower-to-boost-access-supply-for-its-pop" target="_blank" rel="noreferrer noopener">Eli Lilly Releases Cheaper Zepbound Vials Priced Up To 50% Lower To Boost Access, Supply For Its Popular Weight Loss Drug</a>.</li>
</ul>

Guidance

Health Care

Movers

General

Patterson CEO Blames Q1 Drag On Change Healthcare Cyberattack, 'Timing Of Corporate Expenses'

WIIM

Patterson Companies shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS and sales.

Patterson Companies Reaffirmed 2025 Adjusted EPS Guidance Of $2.33-$2.43 Versus Consensus Of $2.36

Patterson Cos Q1 2025 Adj. EPS $0.24 Misses $0.32 Estimate, Sales $1.542B Miss $1.591B Estimate

Sentiment on Wall Street could be guarded until Nvidia Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40585459/nvidia-stock-q2-earnings-preview-analyst-says-ai-cycle-far-from-over-company-has-fi">earnings are in the rearview mirror. </a>The index futures are barely holding up early Wednesday. Given the absence of any major catalyst, stocks could tread water and could move about listlessly. That said, the retail space could see some strength, encouraged by Nordstrom, Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) earnings, while some positive tech earnings could bolster sentiment toward that space.
Market strategist Ed Yardeni said in Yardeni Research&#8217;s weekly preview that Nvidia earnings are a function of AI investments by mostly other large-cap tech companies, making the AI stalwart the fulcrum of not only the AI trade but a big portion of the entire stock market rally. &#8220;Nvidia&#8217;s earnings will begin to be supported by rising demand from other tech and many non-tech companies in the S&amp;P 493,&#8221; he said.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.09%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.06%</td>
</tr>
<tr>
<td>Dow</td>
<td>-0.01%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.05%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Wednesday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.08% to $562, and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) gained 0.11% to $477.28, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session 
U.S. stocks meandered back and forth across the unchanged line on Tuesday before ending higher, with IT stocks providing the thrust. After a negative start, the indices recovered after a report showed consumer confidence rose to the highest since February amid an improvement in inflation expectations. The averages went about in a listless manner and yet had enough momentum to close in the green.
The Dow Industrials scaled a fresh closing high, although the 30-stock blue-chip average could not break above its intraday high. The S&amp;P 500 inched further toward its record close of 5,667.20 hit on July 16, while small-caps fell for a second straight session following their recent runup. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+0.16%</td>
<td>17,754.82</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+0.16%</td>
<td>5,625.80</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+0.02%</td>
<td>41,250.50</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.67%</td>
<td>2,203.00</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Fund manager Louis Navellier expects the market to rally through the presidential election. &#8220;Historically, the stock market rallies into Presidential Election Day since the candidates are promising voters everything and anything,&#8221; he said, adding that &#8220;no taxes on tips and social security benefits are very popular, as are larger child tax credits, plus aid for first-time homeowners.&#8221;
Upcoming Economic Data
<ul>
<li>The Energy Information is due to release its weekly petroleum status report at 10:30 a.m. EDT.</li>
<li>Atlanta Fed President Raphael Bostic&#8217;s speech will make a public appearance at 6 p.m. EDT.</li>
<li>The Treasury will auction five-year notes at 1 p.m. EDT.</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Stocks In Focus:
<ul>
<li>Nordstrom rose about 8% <a href="https://www.benzinga.com/premarket">in premarket trading</a> following the company&#8217;s quarterly results.</li>
<li>Other stocks moving on earnings are Ambarella, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) (up over 23%), Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) (up over 7.50%), nCino, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) (down over 12.5%), PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) (down over 8%), Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) (up over 4%)and SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) (up over 2%).</li>
<li>Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>), Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>), Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>), J. M. Smucker Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>), Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>), Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) and Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) are among the key companies reporting their earnings ahead of the market open.</li>
<li>Those reporting after the close include Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), &nbsp;Cooper Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>), CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>), Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>), HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>), Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>), NetApp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>), Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>), Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) and Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>).</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is extending the <a href="https://www.benzinga.com/trading-ideas/short-ideas/24/08/40579899/super-micro-computer-stock-falls-on-short-report-hindenburg-says-company-has-accounting">weakness seen on Tuesday on the back of a short report.</a></li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil and gold futures extended their weakness and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) retreated below the $60K level. The yield on the 10-year Treasury note fell 1.1 basis points to 3.822%.
Asian stocks closed Wednesday&#8217;s session on a mixed note, while European stocks were firmer in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40594093/economist-peter-schiff-warns-fed-may-be-committing-mistake-by-lowering-rates-in-sep">Economist Peter Schiff Warns Fed May Be Committing Mistake By Lowering Rates In September As Dollar Index Falls To Lowest In Over A Year</a></li>
</ul>
Photo via Shutterstock

Equities

Futures

Previews

Economics

Federal Reserve

$BTC

AFRM

AMBA

CHWY

CRWD

FIVE

NCNO

NTAP

NTNX

NVDA

OKTA

SMCI

SMTC

VSCO

Nasdaq, S&P 500 Futures Flatline As Traders Await Earnings Report From AI Barometer Nvidia: Fund Manager Says Market Could Hold Up Until Presidential Election

Bola Technologies, Inc. (Bola AI), the leading provider of Voice-AI technology for dental professionals has announced a new software integration with Patterson Dental Supply, Inc., a subsidiary of Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) within their Fuse practice management software and Eaglesoft practice management software. This new integration enables dental practices to lessen the burden on busy hygienists by streamlining clinical documentation and charting tasks.

Bola AI Integrates Voice-AI Technology with Patterson Dental Software, Easing Workload for Dental Hygienists

DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Wednesday.</a>
The company reported second-quarter adjusted earnings per share of 49 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g40061613/dentsply-sirona-reports-second-quarter-2024-results-and-announces-second-phase-of-transformation" rel="noreferrer noopener">missing the street view of 50 cents,</a> and quarterly sales of $984 million, missing the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">analyst consensus of $995.66 million</a>.
According to William Blair analyst Brandon Vazquez, largest miss came from Connected Technology Solutions (equipment), <a target="_blank" href="https://www.benzinga.com/quote/XRAY/analyst-ratings" rel="noreferrer noopener">which was down 16% on an organic basis.</a>
&#8220;Our second quarter results were unfavorably impacted by lower demand in our Connected Technology Solutions segment due to continued macroeconomic and competitive pressure,&#8221; said Simon Campion, President and Chief Executive Officer.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/asia/24/07/40062747/asia-markets-up-europe-opens-higher-crude-advances-2-6-global-markets-today-while-us-slept" rel="noreferrer noopener">Asia Markets Up, Europe Opens Higher, Crude Advances 2.6% &#8211; Global Markets Today While US Slept</a>
In the second quarter of 2024, the company repurchased $150 million in stock and plans to buy back an additional $100 million in the third quarter.
In his research note, Vazuez adds that end-markets remain challenging, and Dentsply is not immune to headwinds, but the company has levers to pull to help outperform peers (costsavings, unique products, and share buybacks).
The company had $279 million of cash and cash equivalents as of June-end.
The company highlighted its second phase of transformation, where it aims to cut annual operating expenses by $80 million to $100 million over 12 to 18 months.
Dentsply Sirona is also projecting $40 million-$50 million in non-recurring charges to be expensed in 2024 and 2025.
The restructuring plan anticipates a net reduction in the company's global workforce of approximately 2% to 4%.
&#8220;The second phase of our transformation allows us to both fund reinvestment in our business to better position us to drive profitable growth and contribute to our 2026 adjusted EPS target,&#8221; Campion added. As part of this second phase, Andreas Frank, Executive Vice President and Chief Business Officer, will leave Dentsply Sirona in October.
Outlook: Dentsply Sirona forecasts 2024 sales of $3.86 billion to $3.90 billion, below the prior view of $3.91 billion&nbsp;to&nbsp;$3.97 billion. The outlook is also below the consensus of $3.93 billion, with organic growth expected to be flat or down 1%.
The company anticipates adjusted EPS of $1.96 to $2.02, slightly below the consensus of $2.01 and down from the <a target="_blank" href="https://www.benzinga.com//node/38575439" rel="noreferrer noopener">previous range of $2.00 to $2.10.</a>
In a regulatory <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/818479/000081847924000069/xray-20240630.htm" rel="noreferrer noopener">filing</a>, the company disclosed that in July 2024, it delivered a one-year notice of non-renewal in connection with its non-exclusive distribution agreements with Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) for the distribution of dental equipment in the U.S. and Canada.
It is anticipated that Patterson will continue to be one of the company's two largest distributors as a percentage of its global revenue during the one-year notice period.
The company intends to engage in discussions for new distribution agreements with Patterson. However, failure to successfully renegotiate the distribution agreements or secure potential new agreements with another distributor could adversely affect its business, operating results, and financial condition.
Price Action: XRAY shares are trading higher by 3.02% to $27.59 at last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/07/40061267/asml-shares-surge-over-7-as-team-biden-plans-to-exempt-allies-from-new-rule-on-foreign-chip-equipmen" target="_blank" rel="noreferrer noopener">ASML Shares Surge Over 7% As Team Biden Plans To Exempt Allies From New Rule On Foreign Chip Equipment Export To China</a></li>
</ul>

Analyst Color

XRAY

Dentsply Sirona Misses Q2 Targets - Plans Restructuring Plan Amid Weak Demand

In July 2024, Dentsply Sirona Issued A 1-Year Notice To Not Renew Its Distribution Agreements With Patterson Companies, For Dental Equipment In The U.S. And Canada, Planning To Negotiate New Agreements, A Failure To Renegotiate Posing A Potential Material Adverse Effect On Its Business; Co Says Not Expecting A Charge Against Earnings For The Non-Renewal

Evercore ISI analyst Elizabeth Anderson CFA maintained a Hold rating on Patterson Companies (PDCO – Research Report) today and set a price target o...

Patterson Companies: Hold Rating Amid Dental Sector Setbacks and Macroeconomic Challenges

Analyst Allen Lutz of Bank of America Securities reiterated a Buy rating on Patterson Companies (PDCO – Research Report), reducing the price target...

Buy Rating for Patterson Companies: Overcoming Challenges with Growth Potential

In a report released yesterday, Erin Wright from Morgan Stanley maintained a Hold rating on Patterson Companies (PDCO – Research Report), with a pr...

Patterson Companies: A Cautious Hold Amidst Earnings Challenges and Aggressive Cost-Cutting

In a report released yesterday, Jonathan Block from Stifel Nicolaus maintained a Hold rating on Patterson Companies (PDCO – Research Report), with ...

Stifel Nicolaus Sticks to Its Hold Rating for Patterson Companies (PDCO)

Patterson Companies: Unable To Compound Capital At An Advantage (Rating Downgrade)

Patterson declares $0.26 dividend

The Top Five short crowded stocks in each U.S. sector

Patterson Companies acquires companies in UK and U.S.

Deals this week: Chesapeake, Visa, KKR, Mondelēz and more

This week, several dividend stocks are trading close to their 52-week lows. Here is a list of ten such stocks that are also reaching their ex-divid...

Ex-Dividend Date Nearing for These 10 Stocks – Week of October 14, 2024

APLE

ARMK

ASIX

AVNW

BEPC

BIRD

BMBL

BRZHR

CABO

CBRL

CERT

CMTL

DANOY

ECVT

EVTC

GLNG

HRZN

IART

IBDRY

IBDSF

ICMB

INST

LSPD

LWAY

MDLZ

MGRC

MNTK

NAPA

NEWT

NTST

NXDT

OXSQ

REXR

SATS

SDXOF

SIRI

SIVBQ

SPRC

TBNK

TROW

ULCC

VTLE

Press Releases

Patterson Companies Fiscal 2024 Fourth Quarter and Year End Conference Call Scheduled for Tuesday, June 18, 2024

Patterson Companies Reports Fiscal 2024 Fourth Quarter and Year End Operating Results

Patterson Dental Selects Weave as Patient Engagement Platform

Pearl and Patterson Dental Canada Join Forces to Advance Dental AI in Canadian Dentistry

Patterson Companies Releases 2024 Corporate Responsibility Report

Patterson Companies Fiscal 2025 First Quarter Conference Call Scheduled for Wednesday, August 28, 2024

Comments

Patterson Cos

Notizie

Ultime notizie per Patterson Cos (NASDAQ:PDCO) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO